These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37171557)

  • 21. Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice.
    de Sá Quirino-Makarczyk L; Sainz Ugarte MF; Viana Vieira B; Kniggendorf S; Saito Regatieri CV
    Int J Retina Vitreous; 2020; 6():9. PubMed ID: 32467776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two different treatment regimens' efficacy in neovascular age-related macular degeneration in Turkish population-based on real life data-Bosphorus RWE Study Group.
    Erden B; Bölükbaşı S; Özkaya A; Karabaş L; Alagöz C; Alkın Z; Artunay Ö; Bayramoğlu SE; Demir G; Demir M; Demircan A; Erdoğan G; Erdoğan M; Eriş E; Kaldırım H; Onur İU; Osmanbaşoğlu ÖA; Özdoğan Erkul S; Öztürk M; Perente İ; Sarıcı K; Sayın N; Yaşa D; Yılmaz İ; Yılmazabdurrahmanoğlu Z;
    Int J Ophthalmol; 2020; 13(1):104-111. PubMed ID: 31956577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study.
    López Gálvez MI; Arias Barquet L; S Figueroa M; García-Layana A; Ruiz Moreno JM;
    Acta Ophthalmol; 2020 Nov; 98(7):e820-e829. PubMed ID: 32190990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
    Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
    BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
    Augsburger M; Sarra GM; Imesch P
    Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
    Lee AY; Lee CS; Egan CA; Bailey C; Johnston RL; Natha S; Hamilton R; Khan R; Al-Husainy S; Brand C; Akerele T; Mckibbin M; Downey L; Tufail A
    Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
    Butt T; Lee A; Lee C; Tufail A;
    BMJ Open; 2015 May; 5(5):e006535. PubMed ID: 25943370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting: A Multicenter Cohort Study in Japan.
    Yoneda K; Takeuchi M; Yasukawa T; Terasaki H; Yamamoto Y; Jujo T; Wakuta M; Matsubara H; Mitamura Y; Kato A; Kondo M; Kimura K; Takagi H; Gomi F; Sakamoto T;
    Ophthalmol Retina; 2023 Oct; 7(10):869-878. PubMed ID: 37295608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
    Hatz K; Prünte C
    Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens.
    Jiang B; Gao L; Dong S; Hou Q; Sun M; Zhang J; Yu H; Zhang Z; Sun D
    Adv Ther; 2022 Apr; 39(4):1568-1581. PubMed ID: 34817809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
    Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC
    Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V
    J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of Switching from Pro Re Nata to Treat-and-Extend Regimen in Treatment of Patients with Type 3 Neovascularization.
    Kim JH
    Semin Ophthalmol; 2020 Jan; 35(1):33-40. PubMed ID: 31814497
    [No Abstract]   [Full Text] [Related]  

  • 36. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration.
    Hatz K; Prünte C
    Br J Ophthalmol; 2016 Oct; 100(10):1341-5. PubMed ID: 26755642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry.
    Figueras-Roca M; Parrado-Carrillo A; Nguyen V; Casaroli-Marano RP; Moll-Udina A; Gillies MC; Barthelmes D; Zarranz-Ventura J
    Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1463-1470. PubMed ID: 33219442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
    Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
    Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.
    Ferrante N; Ritrovato D; Bitonti R; Furneri G
    BMC Health Serv Res; 2022 Apr; 22(1):573. PubMed ID: 35484540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.